Customer experience solutions provider Concentrix (NASDAQ:CNXC) in Q2 CY2026, with sales up 1.9% year on year to $2.46 ...

Shares of customer experience solutions provider Concentrix (NASDAQ:CNXC) jumped 11.9% in the afternoon session after the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Revenue and profit within guidance as reported A record-high second quarter $258M in cash flow from operations, $242M in adjusted free cash flow ...

Gain Therapeutics got approval from the Food and Drug Administration to launch a Phase 2 study of a treatment for Parkinson's disease. The stock rose 19% to $2.36. Praxis Precision Medicines said the ...

Shares of Concentrix slid after the company cut its full-year outlook and projected third-quarter results behind Wall Street's expectations. Shares were down 23% to $19.47 in after-hours trading on ...

For 2026, Valentine gave guidance for full-year reported revenue of $10.035 billion to $10.180 billion, implying constant currency revenue growth of 1.5% to 3% and a 60 basis point positive impact ...

"Our second quarter marked an acceleration in many areas in the evolution of our business" including "record level of contract signings for our iX Suite of technology, up 400% year-over-year for the ...

Shareholders of Concentrix Corp (Symbol: CNXC) looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the January 2024 covered call at the $90 strike and collect the ...